Question: List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.

Context:
The first active immunization clinical trial with AN1792 in AD patients was halted when a subset of patients developed meningoencephalitis.
The first passive immunotherapy trial with bapineuzumab,
Preliminary results of a prematurely terminated clinical trial where AD patients were actively vaccinated with aggregated Abeta 
strategies based on Aβ1-42 peptide induced encephalomyelitis and possible microhemorrhages.
Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).
Solanezumab's two Phase III trials in AD patients failed to meet endpoints when analyzed independently. 
Unfortunately, the first active vaccine (AN1792, consisting of preaggregate Aβ and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients
Anti-Aβ monoclonal antibodies (bapineuzumab and solanezumab) are now being developed.
several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different.
Several types of Aβ peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact Aβ(42) , active immunization involving the administration of synthetic fragments of Aβ peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against Aβ peptide
An active anti-Aβ vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned
The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce Aβ burden in the brain of AD patients. 
The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-Aβ immunization is able to alter the course if this devastating disease.
Solanezumab is a monoclonal antibody that binds to β-amyloid (Aβ), a protein that plays a key role in the pathogenesis of AD. The drug is currently being investigated in Phase III trials as a disease-modifying treatment for AD. 
The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-Aβ monoclonal antibodies that has been tested in two Phase II trials. 
The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-Aβ immunization is able to alter the course of this devastating disease.

Answer: Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (Aβ) monoclonal antibodies that have been designed for treatment of Alzheimer disease.
Bapineuzumab
Solanezumab
Ponezumab
Gantenerumab
Exact answer: Bapineuzumab, bapineuzumab, Solanezumab, solanezumab, Ponezumab, ponezumab, Gantenerumab